The high mortality rate of bladder cancer is closely related to the high incidence of bladder cancer, high recurrence rate and limited level of early diagnosis of bladder cancer. Bladder cancer is the fourth most common malignant tumor among men and the eighth most common malignant tumor among women. Clinical manifestations are intermittent painless hematuria, urinary tract irritation and urinary difficulty, and in late stage, infiltration around the pelvic floor and distant metastasis may occur, which will lead to corresponding clinical symptoms. Bladder cancer is mostly non-muscle invasive bladder cancer, and transurethral cystectomy is the main treatment option, but the postoperative tumor residual rate is not optimistic, and there are uncertainties in the number of tumors, size, grading, and carcinoma in situ. Some studies claim that the recurrence and progression rates within 1 year after surgery can reach 15%-61% and 1%-17%, respectively. Surgery combined with bladder intravesical adjuvant perfusion therapy is the main option for the treatment of non-muscle invasive bladder cancer at home and abroad, which can effectively reduce the recurrence rate and kill the free tumor tissues/cells after surgery. The prognosis of bladder tumors is related to pathological type and stage. A study in China said that the 1-year, 3-year, and 5-year survival rates of bladder cancer patients were 95.12%, 82.14%, and 63.12%, respectively. There are also studies that the 5-year overall survival rate of bladder cancer patients is 55.4%. Bladder cancer patients should pay attention to it. If bladder tumor is suspected or diagnosed, it is recommended to go to regular hospitals for comprehensive assessment of the condition, follow the doctor’s instructions to cooperate with the treatment, and choose the appropriate treatment plan to avoid delaying the condition.